Myobloc® (rimabotulinumtoxinB) Injection and NeuroBloc®(Botulinum Toxin Type B) Injectable Solution are indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and pain associated with cervical dystonia.
 
MYOBLOC was the first drug approved in the US to reduce the severity of abnormal head position and the neck pain associated with cervical dystonia. When injected into an affected muscle, botulinum toxin type B inhibits the release of the neurotransmitter, acetylcholine, at the motor nerve terminals to allow it to relax.
 
Regulatory approvals in the US, EU and Canada were based on the results from randomized, multi-center, double-blind, placebo-controlled studies in adult patients with cervical dystonia.
 
MYOBLOC is supplied as a ready-to-use, injectable solution in three single-dose vial sizes of 0.5 mL (2,500 U), 1.0 mL (5,000 U), and 2.0 mL (10,000 U) . Unopened vials of MYOBLOC have demonstrated stability when stored at 2-8°C, and are approved for a 36-month shelf life in the EU, and a 48-month shelf-life in the US and Canada.